European Cancer Congress 2013: News

Keep up to speed with the latest developments and breaking news from ECC 2013.

Date Title Topic
29 Sep 2013 ESMO Press Release: New approaches to testing cancer drugs needed - ESMO Commentary Personalised medicine
29 Sep 2013 ESMO @ ECC 2013: A Phase III Study of Tivantinib Plus Erlotinib Did Not Meet a Primary Endpoint in Patients with Locally-advanced or Metastatic, Non-squamous NSCLC Lung and other thoracic tumours - Anticancer agents & Biologic therapy
29 Sep 2013 ESMO @ ECC 2013: Similar Phase III Results Reported for Dovitinib vs. Sorafenib Treatment in Patients with Metastatic Renal Cell Carcinoma Genitourinary cancers - Anticancer agents & Biologic therapy
29 Sep 2013 ESMO @ ECC 2013: Younger Age in Patients with Metastatic Colorectal Cancer Associates with Poorer Outcome Cancer in Special Situations - Gastrointestinal cancers
29 Sep 2013 ECC 2013 Press Release: Promising Results for New Antibody Drug in Non-Small Cell Lung Cancer Patients: Smokers Respond Well Lung and other thoracic tumours - Immuno-oncology
29 Sep 2013 ECC 2013 Press Release: Survival After Cancer Diagnosis in Europe is Strongly Associated with How Much Governments Spend on Health Care Bioethics, legal and economic issues
29 Sep 2013 ECC 2013 Press Release: Colorectal Cancer Screening Works; ‘Irrefutable’ Evidence that Fall in Death Rates is Attributable to Screening Programmes Cancer prevention - Gastrointestinal cancers
29 Sep 2013 ECC 2013 Press Release: Diabetes Increases the Risk of Developing and Dying from Breast and Colon Cancer Cancer prevention
29 Sep 2013 ECC 2013 Press Release: Young Patients with Metastatic Colorectal Cancer are at High Risk of Disease Progression and Death Cancer in Special Situations - Gastrointestinal cancers
29 Sep 2013 ECC 2013 Press Release: Everolimus Slows Disease Progression in Advanced Papillary Kidney Cancer Patients Genitourinary cancers - Anticancer agents & Biologic therapy
29 Sep 2013 ECC 2013 Press Release: Identifying the Disease-Causing Mechanisms in Cancers with an Unknown Primary Site Improves Treatment and Survival Pathology/Molecular biology - Carcinoma of unknown primary site
28 Sep 2013 ESMO @ ECC 2013: Vemurafenib in Patients With RAI Refractory, Progressive, BRAFV600E-mutated Papillary Thyroid Cancer Endocrine cancers - Anticancer agents & Biologic therapy
28 Sep 2013 ESMO @ ECC 2013: Belagenpumatucel-L Therapeutic Tumour Cell Vaccine for Non-Small Cell Lung Cancer Lung and other thoracic tumours - Immuno-oncology
28 Sep 2013 ESMO @ ECC 2013: Phase III Trial Results Favour Lanreotide Therapy in Patients with Gastroenteropancreatic Neuro-Endocrine Tumours Endocrine cancers - Anticancer agents & Biologic therapy
28 Sep 2013 ESMO @ ECC 2013: Phase III FIRE-3 Trial Data Show Most Patients with Wild-Type RAS Metastatic Colorectal Cancer Benefit from First-Line FOLFIRI Plus Cetuximab Treatment Personalised medicine - Gastrointestinal cancers - Anticancer agents & Biologic therapy